What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set
about
Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group PlenaryCore outcome sets for research and clinical practice.Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes.Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs).Exploring neurodevelopmental outcome measures used in children with cerebral malaria: the perspectives of caregivers and health workers in MalawiThe COMET Handbook: version 1.0.Utilizing qualitative data from nominal groups: exploring the influences on treatment outcome prioritization with rheumatoid arthritis patients.Patients' views about treatment with combination therapy for rheumatoid arthritis: a comparative qualitative study.Reliability and Validity of Selected PROMIS Measures in People with Rheumatoid ArthritisPatient goals in rheumatoid arthritis care: A systematic review and qualitative synthesis.A review of patient and carer participation and the use of qualitative research in the development of core outcome setsDeveloping core outcome sets for clinical trials: issues to considerWhen Patients Write the Guidelines: Patient Panel Recommendations for the Treatment of Rheumatoid ArthritisThe use of qualitative methods to inform Delphi surveys in core outcome set developmentHolding on to the indispensable medication--a grounded theory on medication use from the perspective of persons with medication overuse headache.Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritisExpectations of new treatment in rheumatoid arthritis: developing a patient-generated questionnaireThe trials methodological research agenda: results from a priority setting exercise.Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.Integration of clinical and patient-reported outcomes in surgical oncology.Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales.Implementing a patient-initiated review system for people with rheumatoid arthritis: a prospective, comparative service evaluation.Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis.Patients' considerations in the decision-making process of initiating disease-modifying antirheumatic drugs.Unraveling Patient-Preferred Health and Treatment Outcomes in Early Rheumatoid Arthritis: A Longitudinal Qualitative Study.Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).The intensive care delirium research agenda: a multinational, interprofessional perspective.Clinical Practice Guidelines: Incorporating Input From a Patient Panel.Item Development and Face Validity of the Rheumatoid Arthritis Patient Priorities in Pharmacological Interventions Outcome Measures.What really matters? A multi-view perspective of one patient's hospital experience.Development of core outcome sets for effectiveness trials of interventions to prevent and/or treat delirium (Del-COrS): study protocol.'It's this whole picture, this well-being': patients' understanding of 'feeling well' with rheumatoid arthritis.Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change.Identifying the primary outcome for a randomised controlled trial in rheumatoid arthritis: the role of a discrete choice experiment.COSUMO: study protocol for the development of a core outcome set for efficacy and effectiveness trials in posterior segment-involving uveitis.A core outcomes set for clinical trials of interventions for young adults with type 1 diabetes: an international, multi-perspective Delphi consensus study."Like No One Is Listening to Me": A Qualitative Study of Patient-Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis.Core outcome domains for clinical trials in non-specific low back pain.The influence of patient perceptions of disease on medication intensification in daily practice.Exploring the cultural validity of rheumatology outcomes.
P2860
Q28081736-472DFDAC-DDBE-4052-92DC-36EF6371E73CQ30234594-27FAF85D-6168-4C83-A1AE-CA34B7C310C6Q30494910-DEBFB03A-5B79-41FA-8133-15FD85B8360BQ30571178-9CC7A22B-2958-4B4F-887B-DD39F5E1BCB9Q30834493-6CF2964B-B7DE-4A5E-89D3-A4EAAA3C7530Q33877196-3CF10EB2-9B77-4800-B1E8-E032BD34EB21Q33944156-6188BA81-1709-4BC4-8AB6-3BB9D24E7191Q34451206-77186596-C9BB-45B3-94A4-5DC95036114CQ35778642-8818108C-517B-4C81-814C-C7A5664EB67EQ36224398-2D1B9719-7809-45F4-9F0F-8DF332650745Q36310440-081641D7-0D2B-400D-A5EB-BF32D3BA332EQ36320178-4014C7E1-AD04-46B0-A8BE-79F123EEBE6AQ36469884-04F622EF-3B47-4DAC-ABEB-359F849A1817Q36865661-C319BAA3-7F50-4DA8-9470-AA00F74C4F4FQ36898185-DCF998CC-9955-4A7E-829F-5EF89A409673Q36910016-D84230CA-64E1-4BBA-9DC6-A588C7029564Q37333340-FD39DEB9-6542-45B3-906C-AC7D444390C8Q37522571-F6D95CB9-C63C-410C-A6B7-246B14E76C10Q37728501-53988699-D2A6-4DC1-8950-F38BD5F2546EQ38061035-EF0AB700-8DBF-4F2D-849F-DF20BA165E7BQ38133728-7305E4D9-9C16-40FA-8FC0-73235CF5EE6AQ38695360-28F57198-F878-4F42-84D7-FBC35C230AC8Q38815746-4DDD207D-6267-4D45-8B77-890A8EE9AFBDQ39076719-89BFCB63-876B-46E8-A55B-72A7CE8AFCCAQ39178709-F2A4CAF6-C9F2-4613-84FD-6961D5CF5912Q39230189-78C09B7C-5227-473B-B432-9EEC3FEE1115Q39371231-4112C965-1AB8-4416-A09B-4A6F43C060C8Q39377738-D92E7405-9B9A-4BF1-828A-4D43BDE87F39Q40795254-47F710F0-4B93-46E2-AEA6-EE9A969F35ECQ41638721-8F9B98EF-ECD8-4F5E-8768-7D43B1BF00B9Q42172775-3183446A-3653-42F7-A525-8FBC84B3DAB2Q45335446-DE70F75A-6E5B-4F6C-8E8B-41279A261527Q45877225-81D532BC-9087-4E6D-A094-71766755E118Q47102973-29893B6C-BFC4-489B-B063-5F561A854E95Q47107888-398F94BE-EE9C-4F7B-90FA-EF89CBE90B6BQ47158512-8699DE7F-67ED-4305-AA38-77E84528B1ADQ47268517-C7BB272C-9B2D-49F0-932B-749ECC62A133Q49120257-07C767A9-EFE2-4587-BA8C-C5FA3517EB53Q50916277-E101A0B4-3B16-4E3F-AAE2-20B9974C55A9Q51298800-18084581-3316-44B1-84D7-DFF945BF0E98
P2860
What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
What outcomes from pharmacolog ...... he basis of a patient core set
@ast
What outcomes from pharmacolog ...... he basis of a patient core set
@en
type
label
What outcomes from pharmacolog ...... he basis of a patient core set
@ast
What outcomes from pharmacolog ...... he basis of a patient core set
@en
prefLabel
What outcomes from pharmacolog ...... he basis of a patient core set
@ast
What outcomes from pharmacolog ...... he basis of a patient core set
@en
P2093
P2860
P356
P1476
What outcomes from pharmacolog ...... he basis of a patient core set
@en
P2093
P2860
P304
P356
10.1002/ACR.20034
P577
2010-05-01T00:00:00Z